ATHX Athersys Inc.

1.59
+0.2  (+14%)
Previous Close 1.39
Open 1.64
Price To Book 4.42
Market Cap 225375917
Shares 141,745,860
Volume 4,302,043
Short Ratio
Av. Daily Volume 598,201

SEC filingsSee all SEC filings

  1. 8-K - Current report 19522498
  2. 8-K - Current report 181237049
  3. 8-K - Current report 181222264
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163876
  5. 8-K - Current report 181163012

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 enrollment commenced November 2017 (Japan).
Multistem - TREASURE (Japan)
Ischemic stroke
Phase 3 MASTERS-2 trial initiation announced July 31, 2018.
Multistem
Ischemic stroke
Phase 2 enrollment continues but reported May 2018 that enrollment is slower than expected.
Multistem
Acute myocardial infarction
Phase 2a data released January 23, 2019.
Multistem
Acute Respiratory Distress Syndrome

Latest News

  1. Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock?
  2. Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)
  3. Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
  4. Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT
  5. Are Athersys Inc’s (NASDAQ:ATHX) Interest Costs Too High?
  6. Athersys Reports Third Quarter 2018 Results
  7. Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment — Emerging Consolidated Expectations, Analyst Ratings
  8. Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
  9. Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
  10. Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
  11. Global Stem Cell Market Expected to Reach $270.5 Billion
  12. Who Are The Major Shareholders Of Athersys Inc (NASDAQ:ATHX)?
  13. The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
  14. IPOs and Foreign Investment Propel Biotech: 4 Top Picks
  15. Edited Transcript of ATHX earnings conference call or presentation 7-Aug-18 8:30pm GMT
  16. Is Athersys (ATHX) Stock Outpacing Its Medical Peers This Year?

SEC Filings

  1. 8-K - Current report 19522498
  2. 8-K - Current report 181237049
  3. 8-K - Current report 181222264
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163876
  5. 8-K - Current report 181163012
  6. CT ORDER - Confidential treatment order 181068825
  7. 8-K - Current report 181050187
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181004886
  9. 8-K - Current report 18997973
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 18932476